1. Harris WP, Mostaghel EA, Nelson PS, Montgomery B . Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nature 2009; 6: 76–85.
2. Lorenzo G, Tortora G, Armiento FP, Rosa G, Staibano S, Autorino R et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438–3444.
3. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 17: 1654–1663.
4. Pihan GA, Wallace J, Zhou Y, Doxsey SJ . Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 2003; 63: 1398–1404.
5. Fu J, Bian M, Jiang Q, Zhang C . Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007; 5: 1–10.